S. Yamada et al., ABNORMALITY IN PLASMA-CATECHOLAMINES AND MYOCARDIAL ADRENOCEPTORS IN CARDIOMYOPATHIC BIO-53.58 SYRIAN-HAMSTERS AND IMPROVEMENT BY METOPROLOL TREATMENT, The Journal of pharmacology and experimental therapeutics, 283(3), 1997, pp. 1389-1395
The catecholaminergic neuronal activity and the densities of alpha-i a
nd beta adrenoceptors and angiotensin II receptors were simultaneously
determined in BIO 53.58, a model of idiopathic dilated cardiomyopathy
, and F1B control hamsters. Further, we examined the effect of repeate
d p.o. administration of metoprolol on these biochemical parameters. C
ompared with F1B control hamsters, there was a significant decrease in
B-max of specific binding of both (-)-[I-125]iodocyanopindolol and [H
-3]prazosin with a marked elevation of plasma catecholamine (mainly no
repinephrine and epinephrine) concentrations, in BIO 53.58 hamsters at
Ii and 18 weeks of age (severe cardiomyopathic stage), but not at 5 w
eeks of age. On the other hand, the B-max value of myocardial [I-125]a
ngiotensin II binding in BIO 53.58 hamsters was almost identical to th
at in F1B hamsters. These results suggest a development of down-regula
tion of myocardial beta and alpha-i adrenoceptors because of an increa
sed catecholaminergic neuronal activity with aging in BIO 53.58 hamste
rs. Repeated p.o. administration of a relatively low dose (1 mg/kg/day
) of metoprolol for 7 weeks in Ii-week-old BIO 53.58 hamsters caused a
significant increase of myocardial (-)-[I-125]iodocyanopindolol bindi
ng sites with a marked reduction in plasma catecholamine levels; this
indicated a significant recovery to the F1B levels. The improvement of
these biochemical parameters by metoprolol treatment was also accompa
nied by a significant decrease in the fibrosis in the heart in BIO 53.
58 hamsters. These data suggest that catecholaminergic neurons and adr
enoceptors play a part in the development of heart failure in idiopath
ic dilated cardiomyopathy. Consequently, the present study may provide
a further pharmacological basis for the use of beta-1 adrenoceptor an
tagonists in patients with idiopathic dilated cardiomyopathy.